It's an accurate article, and you guys shouldn't shoot the messenger.
I agree SWS has limitations and obviously the analysts have wildly differing opinions on their forecasts so it's all pretty meaningless.
That being said, revenue streams that were expected sooner rather than later are at risk of being delayed (CHF and ARDS likely need further trials, GvHD is still in FDA limbo and may need further trials as well).
I'm genuinely curious why people are expecting these facts wouldn't affect analysts expectations?
News Flash: 9 Analysts Think Mesoblast Limited (ASX:MSB) Earnings Are Under Threat, page-11
-
- There are more pages in this discussion • 220 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.3¢ |
Change
-0.013(1.37%) |
Mkt cap ! $1.021B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 90.5¢ | 89.5¢ | $1.625M | 1.810M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 86487 | 90.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.5¢ | 63386 | 14 |
View Market Depth
| Last trade - 11.51am 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |